Search clinical trials for: Open Label Extension Study

Total 124612 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.

Schizophrenia
Abbott

Completed

Remission in Subjects With Crohn's Disease, Open Label Extension (CLASSICII)

Crohn's Disease

United States
Eli Lilly and Company

Completed

Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension

Benign Prostatic Hyperplasia

Japan
GlaxoSmithKline

Completed

A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™

Hypertriglyceridemia

United States
Solvay Pharmaceuticals

Completed

An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

Advanced Stage Parkinson's Disease

United States, Albania, Argentina, Brazil, Bulgaria, Canada, Chile, Colombia, Latvia, Lithuania, Peru, Russian Federation, Ukraine
University of Sydney

Completed

Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study

Diabetic Macular Oedema

Australia
Novartis Pharmaceuticals

Completed

Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole

Breast Cancer

Mexico
BioMarin Pharmaceutical

Completed

A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels

Phenylketonurias

United States
Biogen

Completed

Open-Label Natalizumab Safety Extension Study

Multiple Sclerosis

United States
Biogen

Completed

Open-Label Safety Extension Study of Avonex

Multiple Sclerosis
Ambrilia Biopharma, Inc.

Completed

Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

Acromegaly

Belarus, Hungary, Serbia, Ukraine, Romania, Slovakia
Solvay Pharmaceuticals

Completed

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

Early Stage Parkinson's Disease

United States, Australia, Czech Republic, Estonia, Germany, India, Italy, Lithuania, Malaysia, Netherlands, Poland, Portugal, South Africa, Taiwan, Thailand
Solvay Pharmaceuticals

Completed

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

Early Stage Parkinson's Disease

United States, Argentina, Belgium, Bulgaria, Canada, Chile, Colombia, Croatia, Finland, India, Israel, Mexico, New Zealand, Peru, Romania, Russian Federation, Serbia, Slovakia, South Africa, Sweden, Ukraine
Astellas Pharma Inc

Completed

Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

Keratoconjunctivitis | Conjunctivitis

Japan
Daiichi Sankyo, Inc.

Completed

Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes

Type 2 Diabetes

United States, Peru, Mexico
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Open Label Extension Study of Bifeprunox

Schizophrenia

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis

Ankylosing Spondylitis
Abbott

Completed

A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.

Migraines

United States
Bellus Health Inc

Unknown

Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
H. Lundbeck A/S

Completed

A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia

Primary Insomnia

Germany
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis

Ankylosing Spondylitis

Belgium
NeurogesX

Terminated

An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain

HIV Infections | Pain | Diabetes Mellitus | Diabetic Neuropathies | Peripheral Nervous System Diseases | Neuralgia | Herpes Zoster | Polyneuropathies
Henan Cancer Hospital

Not yet recruiting

This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell
University of Santiago de Compostela
Hospital Clinico Universitario de Santiago

Not yet recruiting

An Oral Doxycycline Regimen to Prevent Bacteremia Following Dental Procedures

Bacteremia | Endocarditis

Spain
Bristol-Myers Squibb

Not yet recruiting

Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Canada
University of Florida
Cord for Life, Inc.

Recruiting

Open Label Dose Ranging Study Assessing the Safety of Cord Blood Product in Sacroiliac Joint Syndrome (SIJ) (SIJ)

Pain, Back | Sacroiliac; Backache

United States
Nanjing First Hospital, Nanjing Medical University

Not yet recruiting

Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication:A Prospective, Multicenter, Open-label Randomized Controlled Study.

Helicobacter Pylori Infection
Wave Life Sciences Ltd.

Not yet recruiting

A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD (RestorAATion-2)

Alpha-1 Antitrypsin Deficiency
Nutrition & Sante Iberia
Adknoma Health Research

Recruiting

Open-labelled Study to Evaluate the Effect of SE5-OH Tablets on Healthy Women With Menopausal Symptoms

Menopause

Spain
Sunnybrook Health Sciences Centre

Recruiting

Accelerated, Theta-burst Stimulation for the Treatment of Post-concussion Syndrome - Open-label Pilot Study

Post-Concussion Syndrome

Canada
Vertex Pharmaceuticals Incorporated

Not yet recruiting

A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults

Pain
Lund University Hospital

Not yet recruiting

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) (PERELI)

Dedifferentiated Liposarcoma

Sweden, Norway
M.D. Anderson Cancer Center

Not yet recruiting

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Advanced Colorectal Cancer

United States
Qiong Fu

Not yet recruiting

A Prospective, Single Arm, Open Label, Proof of Concept Clinical Study of Sulfasalazine in the Treatment of Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
AstraZeneca
Daiichi Sankyo

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Non-Small Cell Lung Cancer

Spain, Italy, Japan, Brazil, Taiwan, Korea, Republic of, Australia, Austria, Canada, Poland, United States, Belgium, United Kingdom, Turkey, Hungary, Germany, India
Institute of Mental Health, Singapore

Recruiting

An Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Theta Burst Stimulation in Schizophrenia Patients With Persistent Negative Symptoms (NOBLE-TMS)

Schizophrenia; Negative Type

Singapore
Cosima Locher
Brown University; University of Basel

Not yet recruiting

Conditioned Open-label Placebos to Facilitate Opioid Reduction in Patients With Chronic Non-cancer Pain (ROM)

Chronic Non-cancer Pain
AstraZeneca
Daiichi Sankyo

Not yet recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

Non-small Cell Lung Cancer

China, Taiwan, Korea, Republic of, Australia
Dosentrx Ltd.

Not yet recruiting

Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform

Any Solid Oral Medication

United States
Nanjing First Hospital, Nanjing Medical University

Not yet recruiting

Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study

Helicobacter Pylori Infection | Tegoprazan | Furazolidone
Sir Ganga Ram Hospital

Recruiting

Vegetarian Versus Non Vegetarian Based Diet in the Recurrence of Hepatic Encephalopathy in Patients With Cirrhosis: An Open Label Pilot Study

Hepatic Encephalopathy

India
Cabaletta Bio

Not yet recruiting

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Systemic Sclerosis | Scleroderma

United States
M.D. Anderson Cancer Center
Active Biotech AB

Not yet recruiting

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-Essential Thrombocytosis Myelofibrosis

United States
Lindsey Russell, MD
Napo Pharmaceuticals, Inc.

Not yet recruiting

Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome

Short Bowel Syndrome

United States
M.D. Anderson Cancer Center

Not yet recruiting

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Triple Negative Breast Cancer | Stage 1 cT1b-T1cN0M0

United States
Lantu Biopharma

Not yet recruiting

An Open-label Study of a Gene Therapy Product in Beta-Thalassemia

Beta-Thalassemia
Acusurgical

Recruiting

A Prospective, Open-label, Single-center, Study of the ACUSURGICAL Luca System for Treatment of Vitreoretinal Diseases

Vitreoretinal Disease

Belgium
SystImmune Inc.

Recruiting

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Cervical Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Carcinoma | Biliary Tract Cancer

United States
Lantu Biopharma

Not yet recruiting

An Open Label Study of Gene Therapy Product in Spinal Muscular Atrophy Patients

Spinal Muscular Atrophy

3

Subscribe